COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
Vitamin D study #13 of 54
8/15 Early treatment study
Espitia-Hernandez et al., Biomedical Research, 31:5 (Peer Reviewed)
Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study
Source   PDF   Share   Tweet
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients.
All treated patients were PCR- at day 10 while all control patients remained PCR+. The mean duration of symptoms was 3 days in the treatment group and 10 days in the control group.

Espitia-Hernandez et al., 8/15/2020, retrospective, Mexico, North America, peer-reviewed, 5 authors, dosage 8,000IU daily, 4000IU twice daily for 30 days.
risk of viral+ at day 10, 97.2% lower, RR 0.03, p < 0.001, treatment 0 of 28 (0.0%), control 7 of 7 (100.0%), treatment also with IVM and AZ.
Details of all 54 studies
Please send us corrections, updates, or comments.
Submit